STING Agonist Targeted Delivery for Tumor Cytokine Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering STING agonists face challenges in achieving effective cytokine production in disease tissues without causing adverse systemic immune responses, leading to inefficient treatment outcomes for diseases like cancer and autoimmune disorders.
Innovation Solution
Systemic administration of a STING agonist that selectively increases cytokine concentrations in tumor microenvironments or disease tissues, maintaining a favorable therapeutic index by avoiding excessive cytokine production in the bloodstream, thereby minimizing adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If STING agonists are administered systemically to stimulate immune response, then cytokine production in disease tissues is enhanced, but excessive cytokine production in bloodstream causes adverse systemic immune responses
Solution Approach 1:
The patent employs targeted delivery systems including antibodies conjugated to STING agonists, ligand-receptor targeting pairs, and nanoparticle carriers that direct the agonists specifically to tumor microenvironments and diseased tissues. This ensures high cytokine production locally at the disease site while maintaining low systemic cytokine levels, thereby achieving effective treatment without adverse systemic immune responses
Solution Approach 2:
The patent uses targeting molecules such as antibodies, ligands, and nanoparticle carriers as intermediaries to deliver STING agonists to disease tissues. These intermediaries enable selective accumulation of the agonist at the target site through specific binding interactions, allowing differential cytokine production between diseased and healthy tissues
2Productivity
If high doses of STING agonists are used to achieve effective cytokine production, then treatment efficacy increases, but systemic toxicity increases
Solution Approach 1:
The patent achieves high local cytokine production at disease sites through targeted delivery, allowing effective immune stimulation without requiring high systemic doses. The targeting systems concentrate the agonist at the tumor microenvironment, creating a high local concentration that drives cytokine production while maintaining low systemic exposure and minimizing toxicity
Solution Approach 2:
The patent employs antibody-agonist conjugates where the antibody component acts as a targeting vehicle that copies the specificity of natural immune recognition. This allows the STING agonist to be delivered precisely to antigen-positive tumor cells, achieving high local efficacy at low overall doses
Data Source
AI summary
The present invention relates to methods of treating disease states, including cancer, in a human comprising systemically administering a STING agonist, or a pharmaceutically acceptable salt thereof, to said human.